What Hexalyse Treats: Main Uses and Benefits

This medication is commonly used as a local adjunctive treatment for mild sore throats without fever. The product is generally applied in settings marked by temporary physiological imbalance where short-term symptomatic assistance is needed. Hexalyse is relevant for managing symptoms that interfere with daily comfort, such as the pain of swallowing (odynophagia), persistent local soreness, and symptoms related to inflammatory or irritative states. It is often used during phases when symptoms become more noticeable to manage these manifestations, which include symptoms related to physical discomfort in the oropharyngeal area. This supportive therapeutic benefit is appropriate across domains involving symptomatic discomfort in adults and older children.

Quick Fact: Therapeutic Support

Symptom Domain	Key Benefit	Clinical Context
Throat Pain	Provides supportive relief	Initial phase of mild sore throat
Irritation/Soreness	Helps manage functional stability	Episodic situations of symptom escalation
Swallowing Difficulty	Contributes to improved comfort	Used when symptoms become noticeable

Regulatory References

1. Base de Données Publique des Médicaments (ANSM)

Official Eligibility Profile

The eligibility for Hexalyse is defined by strict regulatory guidelines regarding age, hypersensitivity, and specific physiological states. This medicine is officially indicated for use in adults and children from 6 years of age for the local adjunctive treatment of mild oropharyngeal irritation.

---

Who Must Not Use Hexalyse (Contraindications)

Hexalyse is absolutely contraindicated in two main groups:

• Children under 6 years of age.
• Individuals with a known hypersensitivity or allergy to any of the active ingredients (Biclotymol, Lysozyme hydrochloride, Enoxolone) or to any of the excipients.

---

Conditional and Restricted Use

For certain populations, use is either not recommended or requires caution:

• Pregnancy and Breastfeeding: Use is preferably avoided as a precautionary measure due to insufficient regulatory data on the components in these populations.
• Metabolic Conditions: Patients with diabetes or specific hereditary sugar intolerances (e.g., saccharose intolerance) must consider the lozenge's excipient content, as use is generally not recommended in cases of known sugar intolerance.

Interactions with other medicines and products

Official regulatory documentation for Hexalyse defines two primary constraints concerning its use alongside other medicinal products. These constraints are based on avoiding potential interference and preventing inadvertent overdose.

---

Documented Interaction Profile

Product Category	Constraint/Action Required	Regulatory Rationale
Other Local Antiseptics (Mouth/Throat)	Avoid simultaneous or successive use.	Risk of interference, such as antagonism or inactivation, which may diminish the effectiveness of either treatment.
Products Containing Same Ingredients	Do not combine with other products containing biclotymol, lysozyme hydrochloride, or enoxolone.	To strictly avoid exceeding the maximum recommended doses of the active substances.

---

Official Interaction Statements

Hexalyse contains a combination of three active substances: biclotymol, lysozyme hydrochloride, and enoxolone. It is officially stated that the use of other medicinal products containing any of these same ingredients must be avoided to prevent accidental dosage excess. Furthermore, the combination of Hexalyse with any other local antiseptic, whether used at the same time or sequentially, is discouraged. This restriction ensures that the local effect of the formulation is not compromised by a chemical interaction or inactivation caused by other concurrent treatments.

The physiological effect of Hexalyse is achieved through the coordinated, localized action of three components, each targeting a distinct facet of the biological response within the oropharynx.

Dual-Targeted Microbial Mechanism

This domain covers the anti-infective mechanisms of Lysozyme hydrochloride and Biclotymol, focusing on the pathways that maintain bacterial structural integrity. Lysozyme utilizes an enzymatic hydrolysis of the bacterial peptidoglycan layer, while Biclotymol concurrently exerts a disruptive effect on microbial components, leading to the physiological consequence of inhibition of microbial cellular proliferation at the mucosal surface.

Modulation of the Local Inflammatory Cascade

This mechanism is driven by Enoxolone, which acts as a modulator of pro-inflammatory signaling pathways, including the NF-κB system. By inhibiting the molecular release of key inflammatory mediators, this action directly modulates the tissue's exaggerated response, resulting in the physiological outcome of diminished local swelling (edema) and decreased nociceptive signaling resulting from tissue edema.

Mechanism of Localized Drug Reservoir

The mechanism is underpinned by the unique adherence of components like Biclotymol to the oropharyngeal mucosal proteins, creating a localized drug reservoir. This property ensures that high concentrations of all three active substances are sustained at the site of irritation, confining the anti-infective and anti-inflammatory effects entirely to the peripheral tissue for a targeted and concentration-dependent localized action.

How Hexalyse is Used: Official Administration Guidelines

Hexalyse is a combination medication administered according to defined usage parameters. The product is provided as a sucking tablet (comprimé à sucer) for local, oromucosal delivery. The instructions ensure the active ingredients maintain contact with the irritated tissues for the intended duration.

---

Official Dosing and Administration Schedule

Feature	Official Labeled Instruction
Route and Form	Oral route, administered as a Sucking Tablet.
Adult and Child Dose	6 to 8 tablets per 24 hours (6 à 8 comprimés à sucer par 24 heures).
Dosing Frequency	Doses must be distributed throughout the day, respecting a minimum interval of 2 hours between each tablet.
Age Restriction	Approved for Adults and Children over 6 years (Adulte et enfant de plus de 6 ans). Contraindicated for children under 6 years.

---

Key Procedural Instructions

The correct application of Hexalyse depends on the proper administration technique. The tablets must be sucked slowly (Sucer lentement les comprimés), and under no circumstances should they be chewed (sans les croquer), as this may impair the localized effect.

Treatment must be limited to a maximum of 5 days (Le traitement sera limité à 5 jours). The medication must not be used beyond 5 days without seeking medical advice. Additionally, the simultaneous or successive use of other local antiseptics must be avoided to prevent potential interaction.

Research Evidence / Overview of Studies

Research into Drug Activity

Research has explored the drug's role in addressing the condition, which is a therapeutic option for specific patient populations. The drug's activity was explored, focusing on its influence on inflammatory pathways and the NF-kB protein complex.

• In vitro studies reported an alteration in the production of pro-inflammatory cytokines, specifically IL-6 and TNF-alpha.
• Animal models examined whether the drug could interfere with T-cell activation, noting reduced cellular proliferation in treated subjects versus controls.

---

Phase 3 Clinical Trials

The majority of clinical data comes from two multinational, double-blind, randomized, placebo-controlled trials (RCTs). These trials focused on adults diagnosed with chronic, relapsing-remitting symptoms of the target condition.

Efficacy and Symptom Management

Studies examined outcomes in the study population, including changes in symptoms and reported pain levels. The primary outcome was measured using the Condition Severity Index (CSI) after 12 weeks of treatment.

Trial (N)	CSI Mean Change (Active Group)	CSI Mean Change (Placebo Group)
Trial 1 (N=650)	-3.5	-1.2
Trial 2 (N=712)	-3.1	Not applicable

Some studies evaluated changes in relief speed and duration of reduction in symptoms compared to placebo.

Combination Therapy Research

Research has explored whether the combination of the drug with an established corticosteroid is associated with patient outcomes by examining the rate of disease remission. This exploratory analysis involved a smaller cohort (N=150) from the main Phase 3 trial.

• The rate of sustained remission (defined as CSI <2 for six consecutive months) was noted to be higher in the combination group (35%) than in the monotherapy group (21%). This phase was not powered to detect superiority.

---

Safety and Tolerability Profile

The overall safety profile was documented across both Phase 3 trials. Adverse events (AEs) were primarily mild to moderate in severity.

• AEs reported most frequently included headache, mild gastrointestinal upset, and temporary skin irritation noted at injection sites in the study results.
• Analyses of the safety profile in people with mild liver impairment compared liver enzyme levels to the placebo group over the 12-week period.

---

Subgroup Analysis and Long-term Use

A post-hoc analysis explored the drug's use in refractory patients, and research has specifically examined its use in individuals who have not responded to other treatments.

• In this subgroup (N=88), the observed reduction in CSI score was consistent with the overall trial population.
• Long-term follow-up data (up to two years) indicated that the safety profile remained consistent with the initial trials.

Key Studies & References

1. Role of biclotymol-based products in the treatment of infectious sore throat (Review used for mechanism/in vitro data)

Common questions about Hexalyse (FAQ)

Q: What kind of side effects are most commonly reported with Hexalyse?

A: The most notable adverse effect mentioned in official documents is the possibility of allergic reactions, sometimes appearing as skin issues. Regulatory documents classify the frequency of these reactions as not known, which means the rate of occurrence cannot be reliably estimated from available data.

Q: Does Hexalyse cause drowsiness?

A: Official regulatory documents do not list drowsiness as a known or frequent side effect of Hexalyse. Additionally, the Summary of Product Characteristics (SmPC) does not contain a specific warning regarding the drug's influence on the ability to drive or operate machinery.

Q: Is there any risk associated with taking Hexalyse long-term?

A: Official administration guidelines state that treatment with Hexalyse must be limited to a maximum of 5 days. The regulatory label indicates that the medication should not be used beyond this five-day period unless advised by a healthcare professional.

Q: Can Hexalyse interact with common over-the-counter pain relievers?

A: Official documents do not list specific interactions between Hexalyse and common systemic over-the-counter pain relievers. However, the official label advises avoiding simultaneous or successive use with any other local antiseptic product or with products containing the same active ingredients.

Q: Does Hexalyse affect blood pressure?

A: Regulatory safety data and official product documents do not list changes in blood pressure or other cardiovascular effects as known or reported adverse reactions associated with Hexalyse use.

Q: Can Hexalyse cause changes in mood or sleep patterns?

A: Based on regulatory safety data, changes in mood, sleep patterns, or other psychiatric disorders are not listed as known or reported adverse reactions for this medicine.

Q: Can people with kidney issues use Hexalyse?

A: Regulatory documents for this localized treatment do not specify special precautions or require dosage adjustments for people with renal (kidney) impairment.

Q: Are there specific monitoring tests needed while taking Hexalyse?

A: The official product labeling does not require specific routine medical or laboratory monitoring tests for patients using Hexalyse for the intended short duration of treatment.

Q: Can Hexalyse affect the results of lab tests?

A: The official regulatory documents for Hexalyse do not include a general warning that the medicine interferes with or affects the results of standard clinical laboratory tests.

Q: Is Hexalyse the same as other medicines used for similar conditions?

A: No, Hexalyse is a combination medicine that features three distinct active ingredients: Biclotymol, Lysozyme hydrochloride, and Enoxolone. This triple-active composition is what differentiates it from many other oral preparations, which often rely on a single agent.

Q: Is Hexalyse an antibiotic?

A: According to regulatory classifications, Hexalyse is categorized as an Antiseptic and Local Anti-inflammatory Agent. The product is classified as an Antiseptic and Local Anti-inflammatory Agent, not an antibiotic.

Q: What happens if Hexalyse is stopped suddenly?

A: Since Hexalyse is a local, short-term adjunctive treatment, regulatory documents do not include warnings about withdrawal symptoms or negative effects upon abruptly stopping the medication.

Q: Is it normal to feel a slight headache after starting Hexalyse?

A: Headache has been reported as one of the frequently occurring adverse events in clinical trials. It is described as a reported adverse event in the regulatory documents.

Q: Are there different forms of Hexalyse available (tablet, liquid, etc.)?

A: Hexalyse is officially available and regulated only in the form of a sucking tablet (lozenge) specifically designed for local oromucosal administration in the mouth and throat.

Q: Does Hexalyse have any known interactions with alcohol?

A: Official regulatory documents do not list an explicit contraindication or warning against the consumption of alcohol while using Hexalyse.

Q: Can Hexalyse be used by older adults?

A: Yes, the official labeled instructions specify the use for "Adult and child over 6 years." The regulatory documents do not include special dosage instructions or warnings specific to older adults.

Q: What is the typical duration of treatment with Hexalyse?

A: Official instructions state that the total course of treatment with Hexalyse must be limited to a maximum of 5 days. The product label advises that it should not be used beyond five days unless directed by a healthcare professional.

Q: Can Hexalyse be used during the flu season?

A: Hexalyse is officially indicated for the local, adjunctive treatment of minor irritation in the mouth and throat. The medicine is not an antiviral treatment for the flu itself.

Q: Are there specific warnings about Hexalyse and driving or operating machinery?

A: The official regulatory documents for Hexalyse do not contain a specific warning stating that the medicine influences a person's ability to drive or operate machinery.

Q: Is Hexalyse effective for mild symptoms?

A: Official documents indicate that Hexalyse is indicated for the local adjunctive treatment of mild oropharyngeal irritation, which includes minor discomfort or a sore throat.

Q: If I have a known allergy to other medications, can I take Hexalyse?

A: Hexalyse is contraindicated (should not be used) if you have a known hypersensitivity or allergy to any of its three active ingredients (Biclotymol, Lysozyme hydrochloride, Enoxolone) or to any of the excipients in the tablet.

Q: Are there any warnings about sunlight exposure while using Hexalyse?

A: Official regulatory documents do not include a specific warning about photosensitivity (increased sensitivity to light) or the need to avoid sunlight exposure while using Hexalyse.

Q: Can the drug be taken with or without food?

A: The official administration instructions require the tablet to be sucked slowly and not chewed, ensuring prolonged contact with the throat tissues. However, regulatory documents do not specify any required relationship to meal times, such as taking the drug with or without food.

How to Store and Dispose of Hexalyse?

The storage and disposal instructions for Hexalyse sucking tablets are defined in the official regulatory labeling.

---

Storage Requirements

Hexalyse must be stored at a temperature below 25 C to ensure product stability. It is a mandatory requirement to keep the medicine out of the sight and reach of children to prevent accidental use. The product must not be used after the expiry date printed on the outer packaging.

---

Disposal Guidelines

Any unused or expired Hexalyse must be disposed of in accordance with local requirements. The medicine should not be disposed of via wastewater or household trash unless specifically authorized by local environmental regulations. Follow community disposal programs or contact a pharmacist for guidance on discarding unused medication.